Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) finished Wednesday with a subtraction of -$0.21 to close at $14.12, a downside of -1.47 percent. An average of 1,432,800 shares of common stock have been traded in the last five days. There was a gain of $0.65 in the past week, and it reached a new high 17 times over the past 12 months. The last 20 days have seen an average of 1,273,680 shares traded, while the 50-day average volume stands at 1,651,692.
CPRX stock has increased by 10.23% in the last month. The company shares reached their 1-month lowest point of $12.16 on 07/11/23. With the stock rallying to its 52-week high on 01/13/23, shares of the company touched a low of $10.54 and a high of $22.11 in 52 weeks. It has reached a new high 6 times so far this year and lost -24.09% or -$4.48 in price. In spite of this, the price is down -36.14% from the 52-week high.
Insider Transactions
CPRX stock investors should be aware that Catalyst Pharmaceuticals Inc. (CPRX) stock had its last reported insider trading activity 87 days ago on May 15. In this transaction, the insider spent $345,978. Director, Tierney David S, disposed of 30,000 shares at a price of $16.83 on Apr 05. The insider now owns more than $504,900 worth of shares. Prior to that, VP, Treasurer and CFO GRANDE ALICIA went on to Sale 50,000 shares at $16.70 each on Mar 29. An amount of $835,100 was transacted.
Valuation Metrics
Catalyst Pharmaceuticals Inc. (CPRX) has a trailing price-to-earnings (P/E) ratio of 15.99. The stock’s beta is 1.11. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.71, the price-to-book (PB) ratio at 4.47, and the price-to-cash flow ratio at 12.25.
Financial Health
The quick ratio of Catalyst Pharmaceuticals Inc. for the three months ended March 30 was 3.30, and the current ratio was 3.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Catalyst Pharmaceuticals Inc.’s EBITDA margin for the year ending March 30 is 48.24%, while its operating margin for the same period stands at 46.80%. Its gross profit as reported stood at $179.81 million compared to revenue of $214.2 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Catalyst Pharmaceuticals Inc.’s return on assets was 28.70%.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $29.57 million in the quarter, while revenues of $25.47 million were grew 55.22%. The analyst consensus anticipated Catalyst Pharmaceuticals Inc.’s latest quarter earnings to come in at $0.32 per share, but it turned out to be $0.41, a 28.10% surprise. For the quarter, EBITDA amounted to $42.21 million. Shareholders own equity worth $106.08 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Catalyst Pharmaceuticals Inc. (CPRX) price momentum. RSI 9-day as of the close on 09 August was 62.57%, suggesting the stock is Neutral, with historical volatility in this time frame at 32.80%.
As of today, CPRX’s price is $13.98 +4.83% or $0.65 from its 5-day moving average. CPRX is currently trading +10.31% higher than its 20-day SMA and -10.35% lower than its 100-day SMA. However, the stock’s current price level is +22.78% above the SMA50 and +10.66% above the SMA200.
The stochastic %K and %D were 77.70% and 75.07%, respectively, and the average true range (ATR) was 0.41. With the 14-day stochastic at 72.27% and the average true range at 0.43, the RSI (14) stands at 60.53%. The stock has reached 0.26 on the 9-day MACD Oscillator while the 14-day reading was at 0.42.
Analyst Ratings
ROTH Capital downgraded Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Catalyst Pharmaceuticals Inc. (CPRX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CPRX, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is CPRX’s price target for the next 12 months?
Analysts predict a range of price targets between $15.00 and $25.00, with a median target of $24.00. Taking a look at these predictions, the average price target given by analysts for Catalyst Pharmaceuticals Inc. (CPRX) stock is $22.40.
